A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC).
Joo-Young ByunSun-Kyeong ParkBoon Peng NgYi-Shao LiuChae-Rin KimChanhyun ParkPublished in: Expert opinion on pharmacotherapy (2022)
We found that the economic evaluation studies of the first and second generation of EGFR-TKIs and ALK-TKIs varied by the country and study settings, such as comparator and input parameters. In 12 studies, osimertinib (EGFR-TKI) was not cost-effective compared to other first/second EGFR-TKIs, regardless of the study settings. More evidence can be provided about cost-effectiveness of the third-generation TKIs in future research.